After Cutting Back And Clinging On, Will Biotech Bounce Back In 2023?
Tough Conditions Will Persist In 2023
Executive Summary
Industry investors foresee continued hardship for public companies still without compelling clinical data for their assets, plus the growing influence of the US Inflation Reduction Act on biopharma strategy.
You may also be interested in...
Outlook 2023: The Pharma Rollercoaster Shows No Signs Of Slowing Down
What will 2023 bring as the industry faces one of the toughest periods in the last decade? In Vivo asked three industry experts for their views.
The Busiest Dealmakers Of 2022
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: a market snapshot of inflammatory bowel disease; will biotech bounce back in 2023?; Phase III miss for Roche’s Alzheimer’s candidate; how Japan’s top firms did in the quarter; and China showcase hints at policies and strategies.